Loading…
Clinical-stage biotech developing targeted therapies for RAS-pathway cancers, a common oncogenic driver in tumors.
Clinical-stage biotech developing targeted therapies for RAS-pathway cancers, a common oncogenic driver in tumors.
Has no approved product and no sales, so its spending is funded by raising money from investors, and everything rests on trial results and regulatory decisions for a small set of drugs aimed at RAS-pathway tumours. The lead drug, naporafenib, is in pivotal testing.
Moat: none (IP / patents). Clinical-stage biotech with no approved products; value rests on pipeline data.
Headquarters: San Diego, California, US · Founded: 2018 · Employees: 103
Size Erasca (ERAS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $5.04B, the 1182nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $14.41 on 6 Nov 2026.
Performance Over six months the shares gained 42.4%, against +2.5% for the median peer and -1.1% for the United States market (cap-weighted) — 4th highest of 19 in its peer set.
Capital Return on invested capital runs 94.7 points below its cost of capital (8.3% WACC).
Short interest Short interest is 10.6% of the free float (15 Oct 2026).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$2.94M | -$3.11M | -$3.81M | -$3.73M | -$2.64M |
| EBITDA | -$148M | -$128M | -$149M | -$138M | -$245M |
| Net income | -$287M | -$125M | -$162M | -$125M | -$243M |
| Free cash flow | -$98.1M | -$95.6M | -$109M | -$103M | -$118M |
| Capital expenditure | $59,000 | $128,000 | $60,000 | $1.77M | $14.6M |
| Total debt | $44.7M | $47.1M | $51.9M | $55.9M | $55.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Erasca ERAS | $5.04B | +42% | n/a | n/a | n/a | n/a |
| Revolution Medicines RVMD | $41.2B | +36% | n/a | n/a | n/a | n/a |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
| Amgen AMGN | $249B | +40% | +9% | 36% | 7.4× | 1.8% |
| Verastem VSTM | $1.02B | +72% | +3,996% | -183% | 11.1× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ERAS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.8% | +3.5% | 3rd lowest of 20 |
| 6-month return | +42.4% | +2.5% | 4th highest of 19 |
| Distance from 52-week high | -40.6% | -27.9% | 6th lowest of 21 |
| ROIC minus cost of capital | -94.7 pp | +4.5 pp | lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Erasca ERAS | United States | $5.04B | +42% | n/a | n/a | n/a | n/a | n/a |
| SKBP 326030.KS | South Korea | $5.12B | -11% | +39% | 35% | 8.1× | 0.5% | +93.6% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $5.18B | -39% | +14% | 11% | 7.0× | 15.5% | +9.7% |
| IPCA Laboratories IPCALAB.NS | India | $5.22B | +24% | +11% | 17% | 4.9× | 17.8% | +12.2% |
| Sumitomo Pharma 4506.T | Japan | $5.23B | +7% | +11% | 10% | 1.8× | 1.4% | -2.6% |
| Beijing TongRenTang 600085.SS | China | $5.27B | -8% | -17% | 8% | 2.4× | 2.7% | +6.2% |
| Novast Laboratories 301569.SZ | China | $4.82B | n/a | +3% | 27% | 34.4× | 42.6% | +3.1% |
| Travere Therapeutics TVTX | United States | $4.76B | +16% | +49% | -3% | 7.5× | 16.7% | +19.9% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.71B | +3% | -3% | 16% | 1.6× | -6.8% | +3.0% |
| Supernus Pharmaceuticals SUPN | United States | $5.43B | -49% | +16% | 45% | 4.1× | 4.2% | +13.9% |
| PTC Therapeutics PTCT | United States | $5.47B | -11% | -35% | 22% | 3.4× | 8.0% | +35.4% |
| Guangzhou Baiyunshan Pharmaceutical 600332.SS | China | $4.61B | -11% | +1% | 3% | 0.6× | -0.3% | +4.7% |
| Gland Pharma GLAND.NS | India | $5.53B | +69% | +18% | 20% | 7.8× | 28.0% | +13.3% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $4.53B | -17% | +60% | -4% | 3.0× | n/a | n/a |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.53B | +2% | +12% | 33% | 9.8× | 25.2% | +5.5% |
| Camurus CAMX.ST | Sweden | $4.52B | +47% | 0% | 37% | 17.8× | 10.4% | +46.5% |
| Apotex Health APTX.TO | Canada | $5.62B | n/a | +4% | 32% | 3.0× | -13.5% | +4.2% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.47B | +33% | +21% | 16% | 4.3× | 14.9% | +12.7% |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $4.47B | -34% | +227% | 74% | 6.5× | 3.3% | +45.1% |
| Definium Therapeutics DFTX | United States | $4.47B | +51% | n/a | n/a | n/a | n/a | n/a |
| Veradermics MANE | United States | $5.80B | +31% | n/a | n/a | n/a | n/a | n/a |